AnalystBook Research · Company Intelligence

MANNKIND CORP

MNKDNasdaq

Built from MANNKIND CORP's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -11.76 distress zone — historically elevated failure riskWatch
  • Earnings-manipulation signal · Beneish M 0.38 flag raised, worth a closer lookWatch
  • Earnings quality 87/100 accruals in line with cashOK

Where the revenue comes from

Fiscal 2025, as MANNKIND CORP reports it. History and quarterly detail are in the app.

  • Product Revenue$216.5M
  • Royalty$128.1M
  • Product$114.1M
  • License And Service$106.7M
  • Afrezza$74.6M

Leadership changes

From MANNKIND CORP's own filings, the day they're filed.

  • Lauren Sabella · President · appointmenteff. 2025-07-18
  • Burkhard Blank · Chief Medical Officer · departureeff. 2025-05-09
  • Steven B. Binder · Chief Financial Officer · departureeff. 2024-04-22

Latest filings

  • 8-K · Company announcement2026-08-21
  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-07-24
  • 8-K · Company announcement2026-06-02
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about MANNKIND CORP, every answer cited to the official filings🔒
  • The Intelligence Brief — added when MANNKIND CORP's brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.